BACKGROUND: Targeting of Notch signaling with γ-secretase inhibitors (GSIs) has been considered a promising strategy for the treatment of hematological malignancies including multiple myeloma (MM). Here we investigated whether the cytotoxic effect of bortezomib, an agent commonly used in MM, could be enhanced by the addition of a GSI. METHODS: MM cells were treated with GSI, bortezomib or the combination thereof. Apoptosis of MM cells, proteasome activity and Notch signaling activation were determined. The effect of the drug combination was also evaluated in MM cells transfected with the active domain of Notch-1. RESULTS: Using MM cell lines and primary MM cells isolated from the bone marrow of patients with MM we found a strong synergistic effect of bortezomib in combination with one of the GSIs studied. We next investigated the mechanism underlying this synergistic effect and determined that the effect of the drug combination was mainly dependent on the ability of the selected GSI to inhibit proteasome activity in MM cells. CONCLUSION: Our study demonstrates that selected GSIs that inhibit proteasome activity may be successfully used in combination with bortezomib enhancing its anti-MM effect.
BACKGROUND: Targeting of Notch signaling with γ-secretase inhibitors (GSIs) has been considered a promising strategy for the treatment of hematological malignancies including multiple myeloma (MM). Here we investigated whether the cytotoxic effect of bortezomib, an agent commonly used in MM, could be enhanced by the addition of a GSI. METHODS: MM cells were treated with GSI, bortezomib or the combination thereof. Apoptosis of MM cells, proteasome activity and Notch signaling activation were determined. The effect of the drug combination was also evaluated in MM cells transfected with the active domain of Notch-1. RESULTS: Using MM cell lines and primary MM cells isolated from the bone marrow of patients with MM we found a strong synergistic effect of bortezomib in combination with one of the GSIs studied. We next investigated the mechanism underlying this synergistic effect and determined that the effect of the drug combination was mainly dependent on the ability of the selected GSI to inhibit proteasome activity in MM cells. CONCLUSION: Our study demonstrates that selected GSIs that inhibit proteasome activity may be successfully used in combination with bortezomib enhancing its anti-MM effect.
Authors: R Schwarzer; M Kaiser; O Acikgoez; U Heider; S Mathas; R Preissner; O Sezer; B Doerken; F Jundt Journal: Leukemia Date: 2008-06-05 Impact factor: 11.528
Authors: Yulia Nefedova; Daniel M Sullivan; Sophia C Bolick; William S Dalton; Dmitry I Gabrilovich Journal: Blood Date: 2007-11-26 Impact factor: 22.113
Authors: Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa Journal: World J Stem Cells Date: 2014-07-26 Impact factor: 5.326
Authors: Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose Journal: Oncologist Date: 2021-01-02
Authors: P Yu; M N Petrus; W Ju; M Zhang; K C Conlon; M Nakagawa; M Maeda; R N Bamford; T A Waldmann Journal: Leukemia Date: 2014-08-14 Impact factor: 11.528
Authors: R Schwarzer; N Nickel; J Godau; B M Willie; G N Duda; R Schwarzer; B Cirovic; A Leutz; R Manz; B Bogen; B Dörken; F Jundt Journal: Blood Cancer J Date: 2014-06-13 Impact factor: 11.037
Authors: Alexandra Pisklakova; Eileen Grigson; Maria Ozerova; Feng Chen; Daniel M Sullivan; Yulia Nefedova Journal: Cancer Biol Ther Date: 2016-03-02 Impact factor: 4.742
Authors: Hayley M Sabol; Adam J Ferrari; Manish Adhikari; Tânia Amorim; Kevin McAndrews; Judith Anderson; Michele Vigolo; Rajwinder Lehal; Meloney Cregor; Sharmin Khan; Pedro L Cuevas; Jill A Helms; Noriyoshi Kurihara; Venkat Srinivasan; Frank H Ebetino; Robert K Boeckman; G David Roodman; Teresita Bellido; Jesus Delgado-Calle Journal: Cancer Res Date: 2021-08-04 Impact factor: 12.701